ProCE Banner Activity

CME

Preview of ASH 2019: Key Expert-Selected Studies

Conference Coverage
Clinical Thought
Experts highlight key data to help you learn what to expect at the upcoming Hematology meeting in Orlando. The CCO Conference Coverage program will feature downloadable slides and expert commentaries of clinically relevant studies presented at ASH 2019. We will have the information you need to understand and integrate the latest hematology data into your practice.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: December 05, 2019

Expiration: December 04, 2020

No longer available for credit.

Share

Faculty

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Elias Jabbour

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Rami S. Komrokji

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Sujit Sheth

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with hematologic malignancies and disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with hematologic malignancies and disorders
  • Discuss new data on novel agents and therapeutic approaches for patients with hematologic malignancies and disorders
  • Consider emerging clinical data on novel agents and therapeutic strategies that have the potential to improve the outcomes for patients with hematologic malignancies and disorders

Disclosure

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosure

Primary Author

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Celgene, Genentech, Gilead Sciences, Seattle Genetics, and Tempus and fees for non-CME/CE services from Seattle Genetics.

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Acerta, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Pharmacyclics, and Sunesis.

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Elias J. Jabbour, MD, has disclosed that he has received funds for research support from AbbVie, Adaptive, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, Spectrum, and Takeda.

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Rami S. Komrokji, MD, has disclosed that he has received consulting fees from Celgene, Daiichi Sankyo, Jazz, Novartis, and Pfizer.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has disclosed that he has received consulting fees paid to his institution from AbbVie, Amgen, Celgene, Genentech, Janssen, Kite, MedImmune, Merck, and Takeda and funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda.

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Juno, Merck, Novartis, and Takeda and funds for research support from AstraZeneca, Celgene, and Takeda.

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit K. Rampal, MD, PhD, has disclosed that he has received consulting fees from Beyond Spring, Celgene, Constellation, Jazz, Partner Therapeutics, and Stemline and funds for research support from Constellation and Stemline.

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Sujit Sheth, MD, has disclosed that he has received consulting fees from Acceleron and Celgene and funds for research support from ApoPharma, Celgene, CRISPR/Vertex, La Jolla, Novartis, and Terumo.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice Wang, MD, has disclosed that she has received consulting fees from AbbVie, Agios, Amgen, Astellas, Celyad, Daiichi Sankyo, Jazz, Kite, Pfizer, and Stemline and honoraria from Pfizer and Stemline.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael Andrie, PhD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse has received salary/ownership interest from AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 05, 2019, through December 04, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies and disorders.